Survival in patients with AML by race-ethnicity within the TARGET cohort. (A) EFS across entire TARGET cohort by race-ethnicity. (B) OS across entire TARGET cohort by race-ethnicity. (C) EFS among patients with KMT2Ar AML by race-ethnicity. (D) OS among patients with KMT2Ar AML by race-ethnicity. (E) EFS among patients with CBF AML by race-ethnicity. (F) OS among patients with CBF AML by race-ethnicity.